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Abstract In PC12 sympathetic neurons activation and nuclear
translocation of ERK family MAP kinases plays an essential
role in processes underlying nerve growth factor (NGF)-
dependent differentiation. We have recently cloned MKP-3 as
a novel dual specificity phosphatase displaying selectivity
towards inactivation of the ERK1 and ERK2 MAP kinases.
Here we report that in PC12 cells, MKP-3 undergoes powerful
and specific up-regulation by NGF while a number of mitogens
and cellular stresses are ineffective. NGF-stimulated MKP-3
expression appears after 1 h, is maximal at 3 h, and is sustained
for 5 days. This coincides with a critical period of neurite
outgrowth and terminal differentiation. Consistent with a role
mediating inhibition of PC12 cell MAP kinases, NGF-stimulated
ERK2 activation was suppressed considerably following pre-
treatment with fibroblast growth factor and 9-cis-retinal, two
additional differentiation factors found to induce powerfully
MKP-3 expression. Given the clear cytosolic localization of
MKP3 in PC12 cells and sympathetic neurons, these results
suggest a critical role for inactivating ERK MAP kinases in non-
nuclear compartments during essential stages of NGF-mediated
PC12 differentiation.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Extracellular signal-regulated kinase (ERK), c-Jun amino-
terminal kinase or stress-activated protein kinase (JNK/
SAPK) and p38/CSBP/RK (p38) exemplify three major classes
of mitogen-activated protein (MAP) kinase [1^3]. While ERK
activation is linked predominantly to cellular stimulation by
growth factors, oncogenic p21ras and G-protein coupled re-
ceptors, JNK/SAPK and p38 activation follows exposure to
cellular stresses and in£ammatory cytokines [1^3]. Activated
MAP kinases can phosphorylate and regulate many down-
stream targets including additional kinases, receptors, cyto-
skeletal proteins, as well as transcription factors such as
Elk-1, ATF-2, c-Jun and CHOP [1,4^11]. This, together
with observations using speci¢c chemical inhibitors and dom-
inant negative constructs [12^17], highlights a central role for
MAP kinases orchestrating a range of rapid and long-term
changes in cell function.
Of the known functions for activated MAP kinases, good
evidence now supports a key role in processes underlying dif-
ferentiation, survival and death of neurons. Hence, in the
pheochromocytoma cell line PC12, nerve growth factor
(NGF) elicits cell cycle arrest, neurite formation and enhanced
electrical excitability and this is accompanied by prolonged
activation and nuclear translocation of ERK family MAP
kinases [14,18^20]. Extended ERK activation by constitutively
active upstream kinases is also su⁄cient to mimic NGF ac-
tion, while inhibition of this MAP kinase cascade blocks neu-
ronal di¡erentiation [14,15]. In addition, withdrawal of NGF
from terminally di¡erentiated PC12 cells leads to apoptosis
coinciding with a drastic decrease of ERK activity [13,21].
Moreover, use of mutant kinases functioning upstream of
di¡erent MAP kinase pathways indicates that not only ERK
inhibition, but activation of JNK/SAPK and p38 MAP kin-
ases is critical to processes leading to the induction of apop-
tosis in growth factor-deprived cells [13]. Despite the impor-
tance of MAP kinases in neuronal function, mechanisms
responsible for controlling their activation state remain un-
clear.
Activation of MAPK family members requires dual phos-
phorylation on tyrosine and threonine residues and speci¢c
kinases responsible for this modi¢cation have been identi¢ed
[1^3,14^16,22^28]. Cellular phosphorylation is a reversible
process and among the large number of protein tyrosine phos-
phatases, a new class of dual speci¢city phosphatase (DSP)
has recently been recognized as mediating direct and speci¢c
inactivation of MAP kinase activity [29]. Nine DSP genes
have so far been identi¢ed, and signi¢cantly, some appear
highly selective for inactivation of di¡erent MAP kinases.
MKP-3, for instance, is highly selective for inactivating
ERK, while the DSP M3/6 is e¡ective only against the
JNK/SAPK and p38 MAP kinases [30]. Interestingly, many
DSPs display rapid and powerful transcriptional induction by
growth factors and/or cellular stresses indicating an important
mechanism for MAP kinase control [31^37]. Despite the im-
portance of MAP kinases in neuronal function, their regula-
tion by DSPs during di¡erentiation or programmed cell death
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has not yet been studied. As part of an investigation of DSP
functions in embryonic and adult nervous system, we report
here on the regulated expression of the ERK-selective DSP
MKP-3 during NGF-dependent di¡erentiation of PC12 cells.
2. Materials and methods
2.1. Chemicals
RPMI 1640 cell culture medium was obtained from Gibco (Basel,
Switzerland), protein A-Sepharose 4B was from Pharmacia Biotech
Inc. (Uppsala), horse and fetal calf serum were from AMIMED (Bio-
concept, Allschwill, Switzerland). 2.5 S NGF was from Promega
(Madison, WI, USA). [Q-32P]ATP (5000 Ci/mmol) and [32P]UTP
were from DuPont de Nemours International S.A. (Regensdorf, Swit-
zerland). Goat anti-rabbit IgG horseradish peroxidase conjugate was
from Bio-Rad Laboratories (Glattbrugg, Switzerland) or Amersham
International. 9-cis-Retinal was obtained from Sigma (Buchs, Switzer-
land). All other reagents were obtained from Boehringer Mannheim
A.G. (Rotkreuz, Switzerland), Sigma, or local vendors.
2.2. PC12 cell culture
PC12 cells were grown in 10 cm collagen IV coated plates in me-
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Fig. 1. Induction of MKP-3 by NGF and bFGF in PC12 cells. A: PC12 cells were primed overnight in medium containing 1% horse serum
and subsequently treated with 100 ng/ml of NGF or bFGF for the times indicated. RNA extraction and Northern blot analysis were performed
as described in Section 2. Methylene blue staining to visualize ribosomal RNA revealed equal RNA loading. B: To test cycloheximide sensitiv-
ity PC12 cells were stimulated by addition of NGF as indicated above in the presence or absence of cycloheximide (140 WM) followed by incu-
bation for 3 h at 37‡C. 5 Wg of total RNA was electrophoresed, blotted onto nylon and subjected to Northern blot hybridization, as described.
Lane 1: control untreated cells ; lane 2: cells treated with NGF for 3 h; lane 3: cells treated with NGF plus cycloheximide for 3 h. C: To ana-
lyze MKP-3 protein expression following NGF treatment for the indicated period of time, total cellular proteins were extracted as described in
Section 2. 60 Wg of the cellular lysates were resolved in a 10% SDS polyacrylamide gel and Western blot analysis performed using a⁄nity puri-
¢ed MKP-3 rabbit antiserum. This ¢gure shows a representative experiment among several with identical results.
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dium containing 10% (v/v) horse serum and primed overnight in me-
dium containing 1% horse serum before addition of mitogens or NGF
as described [38]. In studies on the activation of MAP kinases, cells
were seeded at a density of 6U104 cells/cm2 in 60 mm on day 0,
primed in 1% horse serum containing medium on day 1 and pre-
treated with growth factors from day 2 on, together with a further
exchange into 0.5% horse serum containing medium.
2.3. RNA extraction and Northern blot analysis
Total RNA extraction, electrophoresis and Northern blot hybrid-
ization were performed as previously described using an antisense
[32P]UTP-labeled riboprobe speci¢c for MKP3 [38,39].
2.4. MKP3 antibody generation and Western blotting analysis
New Zealand White rabbits were immunized with a keyhole limpet
hemocyanin conjugated peptide corresponding to amino acids 95^112
of MKP3. The polyclonal serum was a⁄nity puri¢ed using GST-
MKP3 coupled to DEAE-A⁄-gel Sepharose [39]. For immunodetec-
tion of MKP3, PC12 cells plated on 10 cm dishes and treated for
di¡erent times with NGF were washed twice with ice-cold PBS and
extracted in 100 Wl of ice-cold lysis bu¡er (50 mM Tris-HCl, pH 7.7,
150 mM NaCl, 1% (v/v) NP-40, 10 Wg/ml aprotinin, 10 Wg/ml leupep-
tin, 1 mM benzamidine, 1 mM PMSF, 10 mM NaF, 1 mM sodium
pyrophosphate, 5 mM sodium vanadate and 10 nM calyculin) and
immediately frozen in a dry ice-methanol mixture. Cell extracts were
thawed and rotary mixed for 1 h at 4‡C and insoluble material was
removed by centrifugation at 100 000Ug for 20 min at 4‡C. 60 Wg of
soluble proteins were resolved on SDS-polyacrylamide gels (10%) fol-
lowed by electrotransfer onto nitrocellulose membranes as described
[38].
2.5. ERK2 immunoprecipitations and immunocomplex kinase assay
For immunoprecipitation of endogenous ERK2, cell extracts were
prepared as mentioned above. 150 Wg of soluble proteins were diluted
to a ¢nal volume of 900 Wl with lysis bu¡er and mixed with 2 Wl of
anti-ERK2 polyclonal antibody (#122; generous gift from Professor
C.J. Marshall, Institute of Cancer Research) prebound to a 50% sus-
pension (v/v) of protein A/G-Sepharose beads. The complex was ro-
tary mixed overnight at 4‡C and beads were then sedimented by
centrifugation at 10 000Ug, washed once in 1 ml of bu¡er, three times
in 1 ml of Tris-HCl 10 mM, pH 7.5 and ¢nally resuspended in 30 Wl of
Tris-HCl 10 mM, pH 7.5. Immunocomplex kinase assays were per-
formed as described, using MBP as substrate [30,38]. Every experi-
ment shown in this publication is representative of at least four addi-
tional experiments showing similar or identical results.
3. Results and discussion
Northern blot analysis revealed that MKP-3 mRNA was
undetectable in undi¡erentiated PC12 cells growing in the
absence of NGF (Fig. 1A). However, addition of NGF led
to a powerful induction of MKP-3 mRNA which was max-
imal at 3 h and sustained throughout the following 5 days in
the continual presence of neurotrophic factor (Fig. 1A). It is
of note that the expression of MKP-3 mRNA parallels exten-
sive neurite outgrowth during this period of NGF-dependent
di¡erentiation [18] (data not shown). Interestingly, basic FGF
(bFGF) and 9-cis-retinal are additional factors known to pro-
mote neuronal di¡erentiation or expression of genes charac-
teristic of di¡erentiated PC12 cells [40^42], and both of these
agents also result in induction of MKP-3 mRNA. While
bFGF-stimulated MKP3 mRNA expression displays a time
course which parallels responsiveness to NGF (Fig. 1A), in-
duction in response to 9-cis-retinal is slightly delayed insofar
that maximal expression appears after 6 h of exposure (Fig.
3). In contrast to these observations, MKP-3 mRNA expres-
sion was not induced by any other mitogen or cellular stress
tested including serum, IGF-II, EGF, phorbol esters, dibutyr-
yl cyclic AMP, ultraviolet light, anisomycin, hydrogen perox-
ide, osmotic or heat shock (data not shown). Together, these
observations indicate that induction of MKP-3 in PC12 cells
is a highly speci¢c response to agents promoting or facilitating
neuronal di¡erentiation. This highly selective MKP-3 induc-
tion by neurotrophic agents is in contrast to several other
DSPs (CL100/MKP-1, MKP-2, hVH5) which appear equally
well induced by mitogenic agents, cellular stresses or NGF
(unpublished, [31,37,43]). One additional observation relating
to NGF-stimulated MKP-3 mRNA induction is its sensitivity
to inhibition by the protein synthesis inhibitor cycloheximide.
Indeed, cycloheximide completely inhibited the NGF-medi-
ated expression of MKP-3 mRNA (Fig. 1B), indicating that
MKP-3 is not an immediate early gene and its delayed ex-
pression in PC12 cells re£ects molecular events dependent on
NGF-stimulated protein synthesis. In this respect also, MKP-
3 is distinct from several other DSPs studied in PC12 cells
where, for instance, CL100/MKP-1, MKP-2 and hVH5 all
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Fig. 2. E¡ect of bFGF and EGF pretreatment on NGF stimulation
of ERK2. PC12 cells were primed for 24 h in medium containing
1% horse serum after which bFGF (100 ng/ml), EGF (150 ng/ml) or
vehicle was added following a further exchange into medium con-
taining 0.5% horse serum as indicated in the ¢gure. Cells were then
incubated for 48 h prior to stimulation with NGF (100 ng/ml), after
which ERK2 activity was measured by immunocomplex assay with
MBP as substrate, at the indicated times.
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display a rapid and transient induction characteristic of the
expression of immediate early genes [31,36,37]
To con¢rm that induction of mRNA leads to the synthesis
of MKP-3 protein, PC12 cell extracts were subjected to West-
ern analysis using an a⁄nity puri¢ed polyclonal antibody.
Similar to the pattern of MKP-3 mRNA induction, MKP-3
protein can ¢rst be detected 3 h following challenge with NGF
and thereafter levels increase in parallel with mRNA levels for
up to 6 days (Fig. 1C). As we reported previously for MKP-3
transfected into COS-7 cells [38], endogenous MKP-3 is de-
tected in PC12 extracts as a doublet running as a protein of
42^44 kDa (Fig. 1C). This doublet may be attributed to alter-
native translational initiation at two in-frame 5P methionines
[38]. Previously, MKP-3 has been shown by us and others to
be localized exclusively in cytosolic compartments of a num-
ber of cell types [38,46]. We have also con¢rmed this distri-
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Fig. 3. Induction of MKP3 mRNA by 9-cis-retinal and blockade of NGF-stimulated ERK2 activity by 9-cis-retinal pretreatment. A: PC12 cells
were primed in medium containing 1% horse serum for 24 h after which they were stimulated with 9-cis-retinal (10 WM) in medium containing
0.5% horse serum. At the indicated times total cellular RNA was extracted and 5 Wg analyzed by Northern blot hybridization as described in
Section 2. B,C: PC12 cells were primed in medium containing 1% horse serum for 24 h before addition of vehicle (control) or 9-cis-retinal (10
WM) (9-cis-RA) in medium containing 0.5% horse serum. After incubation for 48 h, cells were stimulated with (+) or without (3) NGF (100
ng/ml) for 5 min and MBP phosphorylation measured in ERK immunocomplex assays. B: Autoradiography of the SDS-PAGE gel showing
NGF-stimulated MBP phosphorylation by ERK2 immunprecipitates after 9-cis-retinal pretreatment. C: Graphical representation of ERK2 acti-
vation measured as incorporation of radioactivity into the band corresponding to MBP upon stimulation with vehicle (gray bars) or NGF for
5 min (black bars). This ¢gure shows the results of a representative experiment among several with identical results.
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bution in PC12 cells by performing cellular fractionation with
subsequent Western blot analysis (data not shown). In this
respect MKP-3 appears distinct from other dual speci¢city
phosphatases which are clearly nuclear in a range of cell types
[35,44,45].
Experiments using puri¢ed proteins as well as expression in
COS cells show that MKP-3 displays clear selectivity for in-
activation of ERK MAP kinase family members [30,38,46,47].
To test for a similar role in PC12 cells, we assessed NGF-
stimulated activation of ERK2 following treatment with
agents inducing MKP-3. Hence, under conditions where
bFGF leads to a robust expression of MKP-3 after 48 h
(Fig. 1A), NGF-stimulated ERK2 activation was completely
abolished (Fig. 2). No inhibition of NGF-stimulated ERK2
was observed following a 48 h exposure to EGF which fails to
induce detectable MKP-3 (Fig. 2). Similarly, treatment with 9-
cis-retinal for 48 h leads to a powerful induction of MKP-3
(Fig. 3A) and this also results in a substantial inhibition of
NGF-stimulated ERK2 activity (Fig. 3B,C). These results in-
dicate that MKP-3 induction is an important factor in proc-
esses inactivating ERK2 enzymatic activity in PC12 cells.
Consistent with this, we found that inhibition of NGF-stimu-
lated MKP-3 expression using cycloheximide (Fig. 1B) abol-
ished the down-regulation of NGF-mediated ERK2 activa-
tion, normally occurring 3^4 h following NGF stimulation
(Fig. 4). These experimental approaches provide strong cir-
cumstantial evidence consistent with the notion that MKP-3
induction in PC12 cells mediates, at least in part, inactivation
of ERK family MAP kinases following stimulation with
NGF. Such an idea is also consistent with a previous report
showing that in vitro dephosphorylation of ERK2 by extracts
of PC12 cells pretreated with NGF for 4 h, but not earlier
times, is blocked by vanadate (a potent inhibitor of MKP-3)
but not by the serine/threonine phosphatase inhibitor micro-
cystine [48].
In this study we demonstrate powerful induction of the dual
speci¢city protein tyrosine phosphatase MKP-3 in PC12 cells
exclusively by agents promoting neuronal di¡erentiation. We
also describe observations consistent with a functional role for
MKP-3 in suppressing NGF-mediated ERK2 stimulation dur-
ing NGF-mediated di¡erentiation. This is in agreement with
highly selective inactivation of ERK1 and ERK2 compared to
JNK/SAPK and p38 MAP kinases seen by in vitro enzymatic
characterization following MKP-3 expression in COS cells
[31,49]. This, together with its late induction by NGF at a
time when ERK2 is known to be phosphorylated and trans-
located into the nucleus [20], could indicate an important role
inactivating selectively cytosolic ERK during neurite out-
growth. Such compartmentalized regulation of ERK MAP
kinases following long-term exposure to NGF may be of fun-
damental importance in molecular processes underlying neu-
ronal di¡erentiation.
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